Pyrexar Medical has bought back the 20% of its company under outside ownership.
Last April, life sciences firm Perseon sold its hyperthermia technology assets to Pyrexar. As part of the deal, Perseon acquired 20% of Pyrexar, along with rights to royalties on future sales of Pyrexar's BSD-2000 device.
Along with the buyback, Pyrexar has also added nine new international distributors to its roster, increased the speed of its manufacturing process, and procured regulatory approval from Taiwan and Korea, the company said.
